Abstract library

65 results for "mixed".
#2855 Whole Exome Sequencing Reveals the Monoclonal Origin of Gastric Mixed Adenoneuroendocrine Carcinomas
Introduction: Gastric mixed adenoneuroendocrine carcinomas (g-MANECs) are rare neoplasms consisting of adenocarcinoma and neuroendocrine neoplastic components. G-MANECs show more malignant characteristics than gastric adenocarcinomas, while molecular mechanisms underlying the co-existence of the two components remains unknown.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: M.D. Shida Yan
Authors: Yan S, Chen X, Zhang R, Song L, ...
#2941 Mixed Urothelial and Neuroendocrine Carcinoma of the Urinary Bladder: Case Report and Literature Review
Introduction: Neuroendocrine tumors (NETs) comprise
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Dr Mohammed Alaeddine Saidi
Authors: Saidi M A, Ghomari S, ...
#3089 Mixed Large and Small Cell Neuroendocrine Carcinoma of the Endometrium: A Case Report and Literature Review
Introduction: Neuroendocrine carcinoma (NEC) is an extremely rare subtype of endometrial cancer which is usually seen among perimenopausal or postmenopausal women. It runs an aggressive course and posts a clinical challenge due to limited treatment options available.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Dr Mary Anne Cruz
Authors: Cruz M A, Uyboco J, ...
#2725 Upfront Surgery in Patients with High-Grade GEP NEN and MINEN: A Nordic Multicenter Study of 201 Patients
Introduction: Surgery is the principal treatment for loco-regional gastroenteropancreatic (GEP) neuroendocrine tumors (NET). However, whether surgery is beneficial in high-grade neuroendocrine neoplasms (NEN) and mixed neuroendocrine-non neuroendocrine neoplasms (MiNEN) is not known.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: MD, PhD Hans-Christian Pommergaard
#2877 Comparison of Digestive and Non-Digestive Neuroendocrine Neoplasm Patient Characteristics and Survival in an ENETS Center of Excellence
Introduction: Since 2016 both digestive neuroendocrine neoplasms (D-NENs) and non-digestive NENs (ND-NENs) cases are treated within NETwerk, an ENETS Center of Excellence
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Timon Vandamme
#2893 Prediction of Survival for Gastrointestinal Neuroendocrine Tumors: A Systematic Review of Clinical Tools
Introduction: Clinical prediction tools aggregate patient and disease information to predict outcomes. Little is known about gastrointestinal neuroendocrine tumors (GI-NET) prediction tools accuracy and utility.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Julie Hallet
Authors: Hallet J, Ho G, Beyfuss K, Chan D, ...
#2896 Comparative Genomic Analysis of High Grade Neuroendocrine Neoplasms across Diverse Organs
Introduction: Grade 3 neuroendocrine neoplasms (G3 NENs), if poorly differentiated, have a median survival of 10-19 months. Little is known regarding biologic differences between G3 NENs from different primary sites, most commonly GI and lung.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Thomas Yang Sun
#2968 Incidence of Rectal NEN and Adherence to Pathology Classification Rules and Treatment Guidelines: Results of the Population Based Cancer Registry in Belgium
Introduction: Classification of rectal NEN (rNEN) changed significantly over the years.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Karen Geboes
#156 Toxicity, response and survival analyses of Peptide Receptor Radionuclide Therapy (PRRT) in treatment refractory metastatic thyroid cancer using Yttrium-90 and Lutetium-177 Labeled somatostatin analogs
Introduction: Medullary thyroid carcinoma (MTC) represents about 3-16% of thyroid cancer. After first line treatment, therapeutic options for locally recurrent or metastasizing tumors include repeated surgery, whenever possible. Doxorubicin containing chemotherapy regimens in iodine-nonavid differentiated thyroid cancer have poor efficacy.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Vikas Prasad
Authors: Prasad V, Budiawan H, Ali S, Hoersch D, ...
#308 Goblet Cell Carcinoid Tumors - A Retrospective Study of Clinical Presentation and Survival
Introduction: Goblet cell carcinoids (GCC) are rare mixed tumors, with partial neuroendocrine differentiation and intestinal-type goblet cell morphology. They usually have a highly malignant potential.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Henning Grønbæk
Authors: Holt N, Villadsen G, Krogh K, Olesen R, ...